DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Neoplasms

Intervention: FDG-PET (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Theo Ruers, PhD, Principal Investigator, Affiliation: Radboud University

Overall contact:
Charlotte Peeters, MD, Phone: +31-24-3611111, Ext: 17365, Email: C.Peeters@chir.umcn.nl

Summary

The purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose (FDG-PET) scanning.

Clinical Details

Official title: Exploratory Study on FDG-PET Scanning in Evaluating the Metabolic Activity of Liver Metastases Before and After Resection of the Primary Tumor in Patients With a Colorectal Malignancy

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection

Detailed description: The goal of this study is to evaluate the activity of liver metastases before and after resection of the primary tumor. Non-invasive assessment of tumor metabolism is possible in vivo by means of positron emission tomography (PET)-scanning. Therefore, FDG-PET scan offers a suitable approach to determine the influence of removal of a primary colorectal tumor on metabolic activity of the liver metastases. The FDG uptake in the liver metastases is quantified by calculating standardised uptake values (SUVs).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Colorectal cancer and synchronous liver metastases

Exclusion Criteria:

- Pregnancy

Locations and Contacts

Charlotte Peeters, MD, Phone: +31-24-3611111, Ext: 17365, Email: C.Peeters@chir.umcn.nl

Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland 6500 HB, Netherlands; Recruiting
Charlotte Peeters, MD, Phone: +31-24-3611111, Ext: 17365, Email: C.Peeters@chir.umcn.nl
Theo Ruers, PhD, Phone: +31-24-3611111, Ext: 17365, Email: T.Ruers@chir.umcn.nl
Additional Information

Starting date: September 2003
Last updated: September 20, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017